Neuromyelitis Optica Clinical Trial
Official title:
Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term remission.
The autologous stem cell transplant used in this research study is an investigational procedure that uses cyclophosphamide (chemotherapy), rabbit antithymocyte globulin (rATG) (a protein that kills the immune cells that are thought to be causing your disease), rituximab (a biologic drug that targets B cells of your immune system), and intravenous immunoglobulin (IVIg) (pooled IgG antibodies from plasma donors with immunomodulatory and anti-inflammatory effects), followed by return of your own previously collected blood stem cells (autologous stem cell transplant). One day of plasmapheresis will also be performed the day prior to admission for stem cell transplant to remove disease-causing antibodies. The ability of this experimental treatment to stop relapses and progression (worsening) of your NMOSD will be assessed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02283671 -
Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
|
Phase 1 | |
| Recruiting |
NCT01024985 -
Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
|
N/A | |
| Recruiting |
NCT04601142 -
Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism
|
||
| Completed |
NCT03942952 -
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
|
||
| Recruiting |
NCT05573711 -
Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
|
||
| Not yet recruiting |
NCT06118398 -
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
|
||
| Recruiting |
NCT05566769 -
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
|
N/A | |
| Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT03350633 -
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05356858 -
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
|
Phase 2 | |
| Recruiting |
NCT05982925 -
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
|
||
| Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
| Terminated |
NCT02398994 -
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
|
Phase 3 | |
| Withdrawn |
NCT02087813 -
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
|
Phase 1 | |
| Terminated |
NCT01339455 -
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02021825 -
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
|
Phase 4 | |
| Active, not recruiting |
NCT04614454 -
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
|
Phase 2 | |
| Recruiting |
NCT03370965 -
Optic Neuritis Differential Diagnosis Study
|
N/A | |
| Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 | |
| Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|